Cargando…
Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelodysplastic syndromes (MDS). Most patients with MDS are older than 60 years and age-associated morbidities limit the patients’ options for curative transplant therapy. Since the development of co...
Autores principales: | Field, Teresa, Anasetti., Claudio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033135/ https://www.ncbi.nlm.nih.gov/pubmed/21415970 http://dx.doi.org/10.4084/MJHID.2010.019 |
Ejemplares similares
-
Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Chen, Yi-Bin, et al.
Publicado: (2009) -
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013) -
Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011) -
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010) -
Prognostic Value of Thrombocytopenia in Myelodysplastic Syndromes After Hematopoietic Stem Cell Transplantation
por: Wang, Hong, et al.
Publicado: (2022)